Reference
- AmankwaKKrishnanSCTisdaleJETorsades de pointes associated with fluoroquinolones: importance of concomitant risk factorsClin Pharmacol Ther200475242715001976
- AnzuetoANiedermanMSPearleJCommunity acquired pneumonia recovery in the elderly (CAPRIE): eff icacy and safety of moxifloxacin therapy versus that of levofloxacin therapyClin Infect Dis200642738116323095
- [AMR] Arlington Medical ResourcesHospital Antibiotic Market Database [online]2004 Accessed on 25 July 2006. URL: http://www.amr-data.com/
- BallPStahlmanRKubinRSafety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studiesClin Ther2004269405015336463
- BallPQuinolone-induced QT interval prolongation: a not-so-unexpected class effectJ Antimicrob Chemother200045557910797074
- Bayer Pharmaceuticals Co.Avelox (moxifloxacin) package insert2005Westhaven, CTBayer Pharmaceuticals
- BignardiGERisk factors for Claustridium difficile infectionJ Hosp Infect1998401159777516
- BertinoJSOwensRCJrCarnesTDGatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factorsClin Infect Dis200234861311830802
- BlondeauJMHansenGMetzlerKLIn vitro susceptibility of 4903 bacterial isolates to gemifloxacin and advanced fluoroquinolonesInt J Antimcrob Agents20032214754
- Bristol-Myers Squibb Co.Tequin (gatifloxacin) package insert2006aPrinceton, NJBristol-Myers Squibb Co
- Bristol-Myers Squibb Co.Dear Health Care Provider letter [online]2006b Accessed 10 April 2006. URL: http://www.fda.gov/medWatch/safety/2006/tequin_DHCP.pdf
- [CDC] Center for Disease ControlIncidence of soft tissue infections: San Francisco General Hospital––1996–2000MMWR200150381411465906
- [CLSI] Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing2006 Sixteenth Informational Supplement. CLSI document M100–S16
- DialSAlrasadiKHuangARisk of Clostridium dificile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studiesCan Med Assoc J200417133815238493
- DiNubileMJLipskyBAComplicated Infections of skin and skin structure infections: When infection is more than skin deepJ Antimicrob Chemother2004533750
- EdmistonCEKrepelCJSeabrookGRIn vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infectionsAntimicrob Agents Chemother20044810121614982797
- [EMEA] European Agency for the Evaluation of Medicinal Products; Committee for Proprietary Medicinal ProductsPoints to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products [online]2006 Accessed 10 April 2006. URL: http://www.coresearch.biz/regulations/cpmp.pdf
- [FDA] Food and Drug AdministrationGuidance for industry: uncomplicated skin and skin structure infections––Developing antimicrobial drugs for therapy [online]1998 Accessed 10 April 2005. URL: http://www.fda.gov/cder/guidance/2566dft.pdf
- FiebelkornKRCrawfordSAMcElmeelMLPractical disc diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococciJ Clin Microbiol2003414740414532213
- FileTMJrTanJSTreatment of skin and soft-tissue infectionsAm J Surgery19951695A Suppl27S33S
- FirsovAALubenkoIYVostrovSNAntistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolonesAntimicrob Agents Chemother2005492642715980331
- ForrestANixDEBallowCHPharmocodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrob Agents Chemother1993371073818517694
- FrazeeBWLynnJCharleboisEDHigh prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infectionsAnn Emerg Med2005453112015726056
- FurlanutMBrolloLLugattiEPharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infectionsJ Antimicrob Chemother200351101612493793
- GandhiPJMenezesPAVuHTFluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patientAm J Health-Syst Pharm20036024798314686224
- GerdingDNClindamycin, cephalosporins, fluoroquinolones, and Claustridium difficile-associated: this is an antimicrobial resistance problemClin Infect Dis200438646814986247
- GiordanoPSongJPertelPSequential intravenous/oral moxifloxacin versus intravenous pipericillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionInter J Antimicro Agents20052635765
- GraffunderEMVeneziaRARisk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobialsJ Antimicrob Chemother200249999100512039892
- GrahamDRTalanDANicholsRLOnce-daily, high dose levofloxacin versus ticaricillin-clavulanate alone or followed by amoxicillin for complicated skin and skin structure infections: A randomized, open label trialClin Inf Dis2002353819
- GuayDTreatment of bacterial skin and skin structure infectionsExpert Opin Pharmacother2003412597512877635
- HagiwaraTSatohSKasaiYA comparative study of the various fluoroquinolone antibacterial agents on the cardiac action potential in guinea pig right ventricular myocardiumJpn J Pharmacol200187231411885973
- IanniniPBCirciumaruIGatifloxacin-induced QTc prolongation and ventricular tachycardiaPharmacotherapy20012136111253862
- JohnsonSGerdingDNClostridium difficile-associated diarrheaClin Infect Dis1998261027349597221
- LeeMCRiosAMAtenMFManagement and outcomes of skin and soft tissue abcesses coused by community acquired methicillin resistant Staphylococcus aureusPediatri Infect Dis J2004231237
- LooVGPoirierLMillerMAA predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortalityN Engl J Med2005353232442916322602
- LubaschAKellerIBornerKComparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteersAntimicrob Agents and Chemother2000442600310991830
- ManholdCvon RolbiekiUBraseROutbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective randomized studyIntensive Care Med1998241327309885888
- MilatovicDSchmitzFBrisseSIn vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolatesAntimicrob Agents Chemother2000441102710722524
- MulliganMEMillerSDMcFarlandElevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficileClin Infect Dis199316suppl 4S239448324125
- NaimiTSLeDellKHComo-SabettiKComparison of community- and health care-acquired methicillin resistant Staphylococcus aureus infectionJAMA200329029768414665659
- NicholsRLSmithJWGentryLOMulti-center, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infectionsSouth Med J19979011932009404904
- NicholsRLOptimal treatment of complicated skin and skin structure infectionsJ Antimicrob Chemother199944192310511393
- NoelARBowkerKEMacgowanAPPharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic modelAntimicrob Agents Chemother2005494234916189103
- Ortho-McNeil PharmaceuticalLevaquin (levofloxacin) package insert2005Raritan, NJ
- OwensRCRisk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointesPharmacotherapy2001213011911253855
- OwensRCQT prolongation with antimicrobial agents: understanding the signif icanceDrugs200464109112415139788
- OwensRCClaustridium difficile-associated disease: An emerging threat to patient safetyPharmacotherapy200626329931116503710
- ParishLCRouthHBMiskinBMoxifloxacin versus cephalexin in the treatment of uncomplicated skin infectionsInt J Clin Pract20005449750311198726
- RaghavanRLindenPKNewer treatment options for skin and soft tissue infectionsDrugs20046416214215257625
- RennieRPJonesRNMutnickAHOccurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the Sentry antimicrobial surveillance programDiagn Microbio Infect Dis20034528793
- StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541137340616231249
- TarshisGAMiskinBMJonesTMOnce-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized studyAntimicrob Agents Chemother20014523586211451697
- TrampuzALaiferGPharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluidAntimicrob Agents Chemother2002463630312384378
- TrampuzAWenkMRajacicZPharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluidAntimicrob Agents Chemother2000441352510770776
- WeberSGGoldHSHooperDCFluoroquinolones and the risk of methicillin resistant Staph aureus in hospitalized patientsEmerg Infect Dis2003914152214718085
- WickershamRMSchweainSLDrug facts and comparisons2005St. LouisWolters Kluwer Health, Inc
- WiseRAndrewsJMMarshallGPharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral and intravenous administrationAntimicrob Agents and Chemother19994315081010348784
- WrightDHBrownGHPetersonMLApplication of fluoroquinolone pharmacodynamicsJ Antimocrob Chemother20004666983
- YapYGCammAJDrug-induced QT prolongation and torsades de pointesHeart20038913637214594906
- YeeSYKutiJLNicolauDPAntimicrobial management of complicated skin and skin structure infections in the era of emerging resistanceSurg Infect2005628395